exprimo.com - | Exprimo

Success! Domain exprimo.com was analyzed on !

DomainsData.org: | Exprimo

Title:

| Exprimo
Age:

14 years old
Alexa Rank:

24,016,567
Total Sites Linking In (Alexa):

0
Domain's IP Country:

Belgium
Status Code:

OK
IP Address:

188.93.157.159
Description:
Keywords:

exprimo.com Whois Information:

1.

Domain Name:

exprimo.com
2.

Domain Age:

14 years old
3.

Name Server 1:

ns3.combell.net
4.

Name Server 2:

ns4.combell.net
5.

Created:

Monday 10. December 2001
6.

Expires:

Saturday 10. December 2016
7.

Domain Registrar:

Ascio Technologies, Inc

Website Important Html Tags:

TAG
TEXT
div
Image
div
Population PK models allow to integrate pharmacokinetic data from different studies, formulations, doses, and populations. We identify complex absorption and elimination pathways and assess sources of variability in drug concentrations in the target population. This allows to support confident clinical dosing, study design, and go/no-go decision.
div
ComplexÂ mechanisms of action and novel drug-targets require advanced PK/PD modellingÂ for interpretation of results. Exprimo has extensive experience withÂ application of cutting edge PK/PD/mPBPK models to accurately predict studyÂ outcomes.
div
A combined PK/PD/disease model allows to include disease progression in the prediction of biomarkers and clinical outcomes for patients. This can enable quick go/no-go decisions early in development, as well as predicting likelihood of trial success and trial optimization in the target population.
div
Scaling/extrapolationÂ from adult PK and PD data to aid in acceptable study designs for children.Â Support for preparation and review of Pediatric Investigation Plan (PIP).
div
Reviewing documents prior to regulatory submission, writing summaries of M&S work. Exprimo consultants can participate in mock advisory committee meetings. Exprimo has extensive regulatory experience and several of our consultants have accompanied drugs to market.
div
We developed Simulo as an efficient tool to run drug trial simulations including complex adaptive protocol designs. We can also support you with optimal design, therapeutic drug monitoring, or custom trainings.
div
Nov 25, 2016
div
During his time at Merck (MSD) our consultant Andreas Lindauer participated in the modeling and simulation team that worked on numerous model-informed approaches to support the development of pembrolizumab (KEYTRUDA), a new monoclonal antibody approved for the treatment of melanoma and other cancer types. Check out a series of recently published articles by this M&S team.
div
Nov 24, 2016
div
Nov 23, 2016
strong
SGS Exprimo
h2
Secondary menu
h2
Main navigation
h2
Mobile menu
h2
Population Pharmacokinetics
h2
Advanced PK/PD Modeling
h2
Drug-Disease Modeling
h2
Pediatrics
h2
Regulatory Consultancy
h2
Simulations
h2
How modeling and simulation (M&S) supported the development of the immuno-oncology drug pembrolizumab
h2
News & Topics

exprimo.com IP Information:

1.

Ip Address:

188.93.157.159
2.

Country:

Belgium
3.

Status Code:

OK
4.

Region Name:
5.

City Name:
6.

Zip Code:
7.

Speed test:

not available

exprimo.com Alexa Information:

5 Websites linking to exprimo.com:
page-meeting.org
cognigencorp.com
occams.eu
page-meeting.eu
simulo.eu

Websites related to exprimo.com:
interstiss.com
chantoun.fr
courrier.yahoo.fr
cravatesbeverley.com

Top Keywords from Search Engines:
exprimo, sgs, carlos lillo sgs, fda guidance on population pharmacokinetics

Site Screenshots:

Screenshot created on

This is a screenshot of exprimo.com, created on
Click on thumb to enlarge the screenshot.

Google Ranking Screenshots:

Screenshot created on

This is a Google Top 10 results' screenshot for keyword | Exprimo created on .
The position for keyword | Exprimo is: 1
Google Ranking Position checked from US (United States of America) Ip Address on .
Click on thumb to enlarge the screenshot.